Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of an opioid molecule for treating dry eye and eyes suffering from allergies

A dry eye, pharmaceutical technology in the field of use of opioid substance molecules for the treatment of dry eye and eyes with allergies, capable of addressing the absence of eye allergies and their consequences

Pending Publication Date: 2022-02-25
H4 ORPHAN PHARMA +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] No treatment specifically for ocular allergies and their consequences, such as dry eye

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of an opioid molecule for treating dry eye and eyes suffering from allergies
  • Use of an opioid molecule for treating dry eye and eyes suffering from allergies
  • Use of an opioid molecule for treating dry eye and eyes suffering from allergies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0058] To investigate this effect on CFTR modulation, the inventors used the Ussing chamber method, invented by the Dane Hans H. Ussing in the late 1950's. This technique allows the study of ion exchanges through the epithelium as they allow the tissue of interest to be kept alive for hours under controlled temperature and media conditions. The positioning of the tissue between the two half-chambers allows to define an apical compartment (corresponding to the lumen of the organ) and a basolateral compartment (corresponding to the blood compartment) and to study the exchange between these two compartments through the tissue.

[0059] This technique is commonly used, and it is particularly suitable for pharmacological approaches to ion transport and to search for molecules of therapeutic interest in the context of ion secretions from epithelial cells. It involves measuring the transepithelial current (called short circuit and denoted Ise). Ise is expressed in amperes relative t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo[4,5-g]isoquinolin-5-yl] -3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

Description

technical field [0001] The present invention relates to the use of chemical substances: (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1 ,3]dioxol[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one ((3S)-6,7-dimethoxy-3-[ (5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-2-benzofuran-1-one) The left-handed and right-handed enantiomers are used in the treatment of dry eye and allergic eyes. [0002] The present invention relates to the use of opioid molecules and pharmaceutical compositions active in the modulation of transmembrane conductance regulator (CFTR) and the modulation of CD63 expression for the treatment of dry eye and allergic eye, and methods of treatment. Background technique [0003] The 2007 Dry Eye Symposium defined dry eye or xerophthalmia as a multifactorial disorder of tearing and causing ocular surface discomfort, visual disturbance, and tear film instability with symptoms of underlying ocular surface damage. It i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4741A61K31/78A61K31/728A61P27/02A61P37/08
CPCA61K31/4741A61K31/78A61K31/728A61P27/02A61P37/08A61K2300/00Y02A50/30
Inventor 加埃唐·泰拉斯凯瑟琳·伯尔
Owner H4 ORPHAN PHARMA